S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.

Thumbs up and down
Biopharma's S&E highs and lows • Source: Alamy

Regeneron Pharmaceuticals, Inc. generated $262m in the first quarter from the sale of its monoclonal antibody cocktail REGEN-COV (casirivimab/imdevimab) against COVID-19, driving a 38% increase in the company's revenues to $2.53bn. Excluding REGEN-COV, company revenues grew 20%, with strong growth of Dupixent (dupilumab) and Eylea (aflibercept) contributing to the gain.

Despite the availability of REGEN-COV, the use of the antibody treatment to prevent mild-to-moderate COVID-19 from progressing to more serious...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.